Onco-Innovations raises C$280K in insider loans as shares drop 67%
What's the deal? Onco-InnovationsDealroom has a profile for this one. Try Dealroom →, a pre-revenue cancer research company, has secured C$280,000 in new loans from its chief medical officer and outside shareholders. The debt financing will fund continued work on its nanoparticle-based drug candidate, ONC010.
Who's lending? Chief medical officer Dr. Islam Mohamed is providing C$200,000, ring-fenced for external research and development providers. The loan carries 1% monthly interest — roughly 12.7% annually — repayable in two equal installments on September 13 and November 13, 2026, with a 3% monthly penalty rate on default.
Why now? The financing lands as market sentiment sours. Onco-Innovations' shares traded at €0.3755 in July 2026, down about 56% since the start of the year and 67% over the prior 12 months.
A separate group of two non-management shareholders contributed the remaining C$80,000 at a steeper 15% annual interest, earmarked for general corporate expenses. Those lenders can demand full repayment at any time.
What could go wrong? The loans are pure debt, not convertible, so they won't dilute shareholders — but they add repayment obligations without closing the company's structural funding gap. With the first tranche due in September 2026, management must either generate pipeline revenue or secure larger financing soon.
The signal: Turning to insiders and existing shareholders for high-interest, short-dated debt is the move of a cash-strapped biotech with few outside options. It buys time to keep research moving, but the steep rates and near-term deadlines signal how tight the runway has become.
Read more: ad-hoc-news
Image credit: National Institutes of Health (NIH)
